Pet Cancer Options

Evidence-Based Treatment Guide

v2.0.0

Your dog was diagnosed with Mammary Carcinoma. Most common tumour in intact female dogs. ~50% malignant. Risk dramatically reduced by early OHE (0.5% risk if spayed before first oestrus, 8% after first, 26% after second). Caudal glands (4th and 5th) most commonly affected. Compare 5 treatment options for dogs including Lumpectomy / Nodulectomy (Small Tumours), Regional or Radical Chain Mastectomy, Surgery + Adjuvant Chemotherapy — with survival times, costs, and what to expect during treatment.

Pet Cancer Options — Mammary Carcinoma

Canine Oncology Treatment Guide

🐕

Mammary Carcinoma

Modified Owen TNM Stages I-V

BreedsPoodleEnglish Springer SpanielBrittany SpanielCocker SpanielEnglish SetterGerman ShepherdPointerDachshund

canine

Epithelial

About This Cancer

Mammary tumours develop in the milk-producing glands and are the most common tumour type in intact (unspayed) female dogs. Approximately half of canine mammary tumours are malignant, and among the malignant forms, carcinomas (arising from the glandular epithelial cells) are by far the most common. The risk is profoundly influenced by reproductive hormones: dogs spayed before their first heat cycle have only a 0.5% risk, rising to 8% after the first cycle and 26% after the second. This dramatic hormonal link is why early spaying is such a powerful preventive measure. The caudal (rear-most) mammary glands are most commonly affected. Prognosis depends on the tumour's size, histological grade, and whether it has spread to lymph nodes or beyond. Inflammatory mammary carcinoma, a distinct and fortunately uncommon subtype, carries a very poor prognosis and is poorly responsive to current treatments.

Modified Owen TNM Staging for Canine Mammary Tumours

Based on tumour size, lymph node status, and distant metastasis. Tumour size is the strongest prognostic factor.

Stage IT1 (<3 cm), N0, M0

Stage IIT2 (3-5 cm), N0, M0

Stage IIIT3 (>5 cm), N0, M0

Stage IVAny T, N1 (regional LN metastasis), M0

Stage VAny T, any N, M1 (distant metastasis)

Prognostic Factors(5)

Tumour sizeStrongest independent prognostic factor. <3 cm: good prognosis; 3-5 cm: intermediate; >5 cm: poor. Each 1 cm increase associated with significantly increased mortality risk.(Sorenmo et al., 2009)

Histological gradeGrade III (poorly differentiated) carries significantly worse prognosis than Grade I.(Pena et al., 2013)

Lymph node metastasisRegional LN metastasis significantly reduces survival (Stage IV). Sentinel lymph node assessment increasingly recommended.(Sorenmo et al., 2009)

Histological typeInflammatory mammary carcinoma has worst prognosis (MST weeks). Simple carcinomas worse than complex. Carcinosarcomas aggressive.

Ki-67 proliferation indexHigh Ki-67 associated with shorter survival and higher metastatic rate.

Minimum Workup(7 steps)

1Fine needle aspirate or incisional biopsy of mass(es)

2Thoracic radiographs (3-view) for pulmonary metastasis

3Abdominal ultrasound (sublumbar lymph nodes, abdominal organs)

4Regional lymph node FNA (inguinal or axillary depending on gland location)

5Complete blood count and serum biochemistry

6Tumour measurement (longest diameter — critical for staging)

7Abdominal/thoracic CT for surgical planning in advanced cases

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength

Lumpectomy / Nodulectomy (Small Tumours)

~18 mo (12–24)

Strong

$800–$2,000

Regional or Radical Chain Mastectomy

~24 mo (12–36)

Strong

$2,000–$5,000

Surgery + Adjuvant Chemotherapy

~18 mo (12–24)

Moderate

$4,000–$8,000

Metronomic Chemotherapy (Cyclophosphamide + Piroxicam)

~12 mo (6–18)

Indirect

$50–$150

Inflammatory Mammary Carcinoma — Palliation

~6 mo (1–8)

Moderate

$50–$200

Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.

Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.

ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.

IndirectEvidence comes from a different tumour type or species and has been applied here.

LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.